Randomised trials in ovarian cancer: trial design considerations

被引：6

作者：

Brady, MF

Thigpen, JT

Vermorken, JB

Parmar, MKB

机构：

[1] Roswell Pk Canc Inst, GOG Stat Off, Buffalo, NY 14263 USA

[2] Univ Mississippi, Sch Med, Dept Med, Jackson, MS 39216 USA

[3] Univ Antwerp Hosp, Dept Med Oncol, Edegem, Belgium

[4] MRC, Canc Trials Off, Cambridge, England

来源：

ANNALS OF ONCOLOGY | 1999年 / 10卷

关键词：

end point selection; progression-free survival; response; survival; trial size;

D O I：

10.1023/A:1008319704310

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Randomised clinical trials are considered the definitive source of evidence for guiding decisions in clinical practice. The concept of a clinical trial is based on sound scientific, ethical, and practical principles. The strength of evidence that an individual trial provides is assessed on the manner in which these principles are incorporated into the design and execution of the trial. Since the way these principles are incorporated into a trial is judgmental, the strength of evidence from an individual trial is a matter of degree. The purpose of this paper is to present some of the scientific, ethical and practical considerations surrounding the selection of endpoints and determination of sample size for trials in ovarian cancer.

引用

页码：75 / 82

页数：8

共 50 条

[21] Restrictive versus goal-directed fluid replacement strategy in ovarian cancer cytoreductive surgery (RiGoROCS): A randomised controlled trial
Goswami, Jyotsna
Pal, Angshuman Rudra
Barman, Suparna Mitra
Sarkar, Anshuman
Patro, Viplab
Bhowmik, Jaydip
Mukhopadhyay, Asima
INDIAN JOURNAL OF ANAESTHESIA, 2023, 67 (12) : 1101 - +
[22] Bisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials
Liu, Yupeng
Du, Chen
Zhang, Yuxue
Zhao, Shu
Zhao, Lina
Li, Pengfei
Hu, Fulan
Zhu, Lin
Liu, Yanlong
Pang, Da
Zhao, Yashuang
BMJ OPEN, 2015, 5 (04):
[23] Measuring Quality of Life in Ovarian Cancer Clinical Trials-Can We Improve Objectivity and Cross Trial Comparisons?
Bhat, Gita
Karakasis, Katherine
Oza, Amit M.
CANCERS, 2020, 12 (11) : 1 - 24
[24] SGO guidance document for clinical trial designs in ovarian cancer: A changing paradigm
Herzog, Thomas J.
Alvarez, Ronald D.
Secord, Angeles
Goff, Barbara A.
Mannel, Robert S.
Monk, Bradley J.
Coleman, Robert L.
GYNECOLOGIC ONCOLOGY, 2014, 135 (01) : 3 - 7
[25] Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma
Escudier, Bernard
Heng, Daniel Y. C.
Smyth-Medina, Arthur
Porta, Camillo
CLINICAL GENITOURINARY CANCER, 2014, 12 (01) : 1 - 12
[26] Endpoints in onocologic Trials A critical Survey on the Example of Ovarian Cancer
Hilpert, F.
Pfisterer, J.
Arnold, D.
ONKOLOGE, 2016, 22 (08): : 586 - 595
[27] Clinical trial considerations for pediatric cancer drug development
Cooner, Freda
Ye, Jingjing
Reaman, Gregory
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (06) : 859 - 874
[28] Involving users in the design of a randomised controlled trial of an intervention to promote early presentation in breast cancer: qualitative study
Forbes, Lindsay J. L.
Nicholls, Carol McNaughton
Linsell, Louise
Graham, Jenny
Tompkins, Charlotte
Ramirez, Amanda J.
BMC MEDICAL RESEARCH METHODOLOGY, 2010, 10
[29] Phase 2 non-randomised trial of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent platinum-sensitive ovarian cancer
Raj, Hemanth
Keerthi, Marri Sri Santosh
Palaniappan, Ravisankar
Prakash, Ujwala
Dhanushkodi, Manikandan
Ganesan, Trivadi S.
ECANCERMEDICALSCIENCE, 2021, 15
[30] Prognostic Factors in Advanced Ovarian Cancer - A Clinical Trial
Dinca, Alexandra Ligia
Birla, Rodica Daniela
Dinca, Valeriu Gabi
Marica, Cristian
Panaitescu, Eugenia
Constantinoiu, Silviu
CHIRURGIA, 2020, 115 (01) : 50 - 62

← 1 2 3 4 5 →